|
TERF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.04099950881675E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.80709949413472E-10 |
| Normal-vs-Stage2 |
3.967300E-04 |
| Normal-vs-Stage3 |
2.92489998887646E-09 |
| Normal-vs-Stage4 |
3.35389999994717E-07 |
| Stage1-vs-Stage2 |
3.556800E-01 |
| Stage1-vs-Stage3 |
1.965050E-01 |
| Stage1-vs-Stage4 |
4.791000E-01 |
| Stage2-vs-Stage3 |
1.084220E-01 |
| Stage2-vs-Stage4 |
2.172800E-01 |
| Stage3-vs-Stage4 |
7.974400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.83010051557631E-10 |
| Normal-vs-AfricanAmerican |
2.606200E-02 |
| Normal-vs-Asian |
3.61859999997716E-06 |
| Caucasian-vs-AfricanAmerican |
7.542400E-02 |
| Caucasian-vs-Asian |
7.755800E-01 |
| AfricanAmerican-vs-Asian |
1.595830E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.45390000039214E-08 |
| Normal-vs-Female |
3.83880038867801E-10 |
| Male-vs-Female |
6.603600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.97680002869782E-09 |
| Normal-vs-Age(41-60Yrs) |
3.07819999489922E-08 |
| Normal-vs-Age(61-80Yrs) |
8.57790000141634E-08 |
| Normal-vs-Age(81-100Yrs) |
1.244690E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.577800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.755800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.476400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.121600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.333400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.204200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.158800E-03 |
| Classical-VS-Follicular |
2.963800E-02 |
| Classical-VS-Other |
1.741000E-01 |
| Classical-VS-Normal |
2.12659999609954E-08 |
| Tall-VS-Follicular |
2.684800E-01 |
| Tall-VS-Other |
9.646400E-01 |
| Tall-VS-Normal |
2.87779999830207E-09 |
| Follicular-VS-Other |
6.725000E-01 |
| Follicular-VS-Normal |
3.88969999542965E-08 |
| Other-VS-Normal |
3.475500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.9841999678365E-09 |
| Normal-vs-N1 |
2.94359980834713E-10 |
| N0-vs-N1 |
1.345670E-02 |
|
|
